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Design
Total population /
SAT vs. DAPT
Mean
age Male
Second
antiplatelet
Duration
of DAPT Follow-up Valve
Durand 2014 Prospective
cohort
292 / 164 vs 128 83.6 y 48% Clopidogrel 1 mo 30 days CoreValve,
SAPIEN
Poliacikova 2013 Retrospective
cohort
149 / 91 vs 58 82 y 54% Clopidogrel 6 mo 30 days,
6 mo
CoreValve
SAT-TAVI 2014 RCT 120 / 60 vs 60 81.1 y 33% Clopidogrel or
ticlopidine
6 mo 30 days,
6 mo
SAPIEN XT
Ussia 2011 RCT 79 / 39 vs 40 81 y 46% Clopidogrel 3 mo 30 days,
6 mo
CoreValve
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Six Versus Twelve Months of Dual Antiplatelet Therapy After Implantation
of Biodegradable Polymer Sirolimus-Eluting Stent: A Randomized
Substudy of the I-LOVE-IT 2 Trial
Yaling Han,1 Kai Xu,1 Quanmin Jing,1 Jing Li,1 Yi Li1
1General Hospital of Shenyang Military Region, Shenyang, China
BACKGROUND There are no reports on a large-scale randomized trial
exploring optimal dual antiplatelet therapy (DAPT) duration after
biodegradable polymer sirolimus-eluting stent (BP-SES) implantation.
We sought to report the 18month follow-up of randomized substudy
of the prospective I-LOVE-IT 2 trial, which compared safety and efﬁ-
cacy between patients receiving 6- vs. 12-month DAPT after implan-
tation of a novel BP-SES.
METHODS In the prospective randomized I-LOVE-IT 2 trial, 1829 pa-
tients who were allocated to the BP-SES group were also randomized
to receive either 6-month (n¼909) or 12-month DAPT (n¼920). The
endpoints of this substudy included 18-month TLF, and 18-month net
adverse clinical and cerebral events (NACCE), a composite of all-cause
death, all MI, stroke, and major bleeding (Bleeding Academic Research
Consortium [BARC] type 3 bleeding).
RESULTS At 18 months, there was no difference in TLF between 6-
month DAPT and 12-month DAPT groups (7.5% [68/909] vs. 6.3% [58/
920], Log-rank p¼0.32). The 18-month incidence of NACCE were also
similar between the groups (7.8% [72/909] versus 7.3% [67/920], Log-
rank p¼0.60), or its individual endpoint components. Landmark an-
alyses also showed that there was no signiﬁcant difference of NACCE
through 6-18 months between the groups (Log-rank p ¼ 0.32). No
deﬁnite/probable stent thrombosis occurred between 6 and 18 months
in either group; however, there was arithmetically higher all-cause
mortality in the 12-month group compared to the 6-month group
(0.7% vs. 1.3%, p¼0.16) in the same time interval.
CONCLUSIONS The present study indicated noninferiority in safety
and efﬁcacy of 6- vs. 12-month DAPT after implantation of a novel BP-
SES and low 18-month stent thrombosis in both treatment arms.
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BACKGROUND Major bleeding episodes or strokes can occur in up to 25%
of transcatheter aortic valve replacement (TAVR). Although guidelines
recommend dual antiplatelet therapy (DAPT) up to 6 months, they also
recognize there is a lack of evidence comparing antiplatelet strategies in
TAVR. Previous studies were not powered for individual, but rather com-
posite end-points. We aimed to perform a meta-analysis comparing single
antiplatelet therapy (SAT) to DAPT in TAVR.
METHODS PubMed, EMBASE, Cochrane, and conference abstracts were
searched for observational and randomized studies that directly compared
SAT to DAPT in patients undergoing TAVR. Odds-ratios of safety and ef-
ﬁcacy outcomes were computed using random or ﬁxed-effects models.
Heterogeneity was examined with Cochran Q test and I2 statistics. Meta-
analysis statistics were performed with Review Manager 5.1.
RESULTS Four studies and 640 patients were included, of whom 354
(55%) received SAT. In the DAPT group, two antiplatelet agents were
given for up to 6 months (Table 1). In a 30-day follow-up, SAT was
associated with a decreased incidence of major vascular
complications (OR 0.53; p¼0.07), any vascular complication (OR
0.42; p<0.01), major bleeding (OR 0.27; p<0.01; Figure 1), life-
threatening bleeding (OR 0.41; p¼0.02), and any bleeding episode
(OR 0.44; p¼0.03). There were no signiﬁcant differences between
SAT and DAPT in all-cause mortality (p¼0.57), cardiovascularmortality (p¼0.99), major stroke (p¼0.42), or any stroke/TIA
(p¼0.64). Similar results were observed in the 6 month follow-up.CONCLUSIONS This meta-analysis suggests that SAT is safer than
DAPT in terms of vascular complications and major or life-threatening
bleeding episodes after TAVR. Further, our results indicate that a
single antiplatelet agent is as effective as DAPT in the prevention of
cerebrovascular events. Our study is hypothesis-generating; larger
randomized trials are warranted to conﬁrm these ﬁndings.
CATEGORIES STRUCTURAL: Complications
KEYWORDS Antiplatelet therapy, Complication, TAVRHYPERTENSION THERAPIES AND
RENAL DENERVATION
Tuesday, October, 13, 2015, 2:00 PM-4:00 PM
Abstract nos: 83 - 90TCT-83
Long-term (24-month) blood pressure results of catheter-based renal
artery denervation: SYMPLICITY HTN-3 Randomized Controlled Trial
Deepak L. Bhatt,1 George L. Bakris2
1Harvard Medical School, Boston, MA; 2University of Chicago Medicine,
Chicago, Illinois
BACKGROUND In previous unblinded trials of renal denervation
(RDN), the reduction in blood pressure (BP) was stable or further
increased over time. The SYMPLICITY HTN-3 trial is the ﬁrst ran-
domized blinded controlled trial of RDN (N¼364) vs. sham control
(N¼171) where both the patient and BP assessor were blinded to
treatment allocation until assessment of the 6-month primary
endpoint. Patient behavior speciﬁc to drug adherence was believed to
be one important factor underlying the marked 6-month BP reduction
seen in the control arm, supported by changes in ambulatory and
ofﬁce BP measurement at 12 months when subjects were unblinded.
Long-term (24-month) outcomes will provide further insights into
whether BP trends seen in both the RDN and control cohorts at 12
months persist or are accentuated.
METHODS The SYMPLICITY HTN-3 trial enrolled subjects with ofﬁce
systolic BP 160 mm Hg despite being on an average of w5 antihy-
pertensive medications, including a diuretic, at least 3 of which were
at maximally tolerated doses. While the 6-month primary safety
endpoint was met, ofﬁce and ambulatory BP did not differ between
RDN and sham groups in part due to marked BP reduction in the
control group. After 6 months, subjects were unblinded and those in
the sham group meeting eligibility requirements could undergo RDN
(crossover group) while some subjects chose not to undergo RDN or
were not eligible (non-crossover group).
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months following unblinding showed a decrease of BP in the RDN
arms over time and an increase in BP in the control/non-crossover arm
from 6 to 12 months as assessed by both ofﬁce and ambulatory BP
(Figure). Outcomes at 24 months, including ofﬁce and ambulatory BP,
available at TCT 2015, will be important to assess whether this pattern
is maintained. Long-term safety will also be presented.
CONCLUSIONS The ofﬁce systolic BP reduction in the RDN arm
continued to increase between 6 and 12 months while the opposite
relationship existed in the non-crossover patients. Outcomes at
24 months of unblinded treated subjects and non-treated control
subjects will provide new insights to guide our continued under-
standing of the effects of patient selection, medication burden, and
medication adherence in patients with treatment-resistant hyperten-
sion as well as conﬁrm long-term safety in this large population
treated with RDN.
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BACKGROUND Posthoc analysis of SYMPLICITY HTN-3 has revealed a
trend for greater blood pressure reductions with increasing number of
ablations and highlighted the difﬁculty of achieving uniform and
circumferential ablation pattern using single electrode renal dener-
vation catheters. We examined whether iterative low power multi-
electrode bipolar-unipolar treatments based on local closed-loop
temperature sensing can provide effective four quadrant ablations.
METHODS Ten porcine renal arteries were treated once (n¼4) proxi-
mally or twice in sequence (n¼6) w6mm distal to the aortic ostium of
the renal artery using the ReDy system with a 72C set point (1.10.5
W, n¼10). A low proﬁle, 9-electrode, over-the-wire, RF ‘basket’ catheter
with closed loop temperature control, and a smart generator delivers
a 60sec sequence of bipolar and unipolar treatments designed to
ensure that each electrode meets a temperature-duration objective.
Catheters were advanced into the renal artery and positioned for
treatment using a 6-Fr guiding sheath under ﬂuoroscopic guidance.
In the dual treatment group the catheter was retracted half a basket
length after the ﬁrst treatment. At 7 days post treatment, kidneys
were harvested for norepinephrine (NEPI) quantiﬁcation and arteries
processed for histopathology. Post treatment NEPI levels were evalu-
ated relative to our published baseline levels (666222 ng/g, n¼12)
to calculate percent reductions. Automated image processing of H&Estained tissue sections estimated the percentage of affected circum-
ference up to a depth of 5 mm from the lumen.
RESULTS There was no angiographic evidence of acute dissection,
perforation, or occlusion at the time of the procedure or subsequently.
Histologically all treated arterial sections exhibited advanced re-
endothelialization, with progressive arterial and peri-arterial repair,
and no evidence of adverse effects on arteries or surrounding tissue.
Summation of ablation effects over multiple tissue sections revealed
that a larger percentage of the total circumferential arc was affected
by dual treatments compared to single treatments up to 3 mm from
the lumen. The difference between single and dual treatments was
particularly pronounced up to 1 mm away from the lumen, 53.531.6%
vs 87.511.2% (p¼0.11) and appeared to predict relative NEPI reduc-
tion, 60.638.5% (p¼0.03) vs 88.117.0% drop (p<0.001).
CONCLUSIONS We and others have argued for distal treatments
based on the relative accessibility of target nerves, yet such treat-
ments carry greater risk of affecting surrounding organs, particularly
close to the hilus. The data herein illustrate that low power dual distal
treatments using the Renal Dynamics ReDy system provide effective
circumferential ablation without affecting arterial patency or sur-
rounding organs.
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BACKGROUND Percutaneous sympathetic renal artery denervation is
available for the treatment of patients with resistant hypertension.
We further investigated the safety and efﬁcacy of a multi-electrode
renal denervation system (EnligHTN) in patients with severe un-
controlled hypertension.
METHODS The EnligHTN-II study is a post-market clinical investiga-
tion in which patients were assigned to one of three groups; Group A,
ofﬁce systolic BP (OSBP) 160 mmHg and estimated glomerular
ﬁltration rate (eGFR) 45 mL/min per 1.73 m2, Group B, OSBP 140-
159 mmHg and eGFR 45 mL/min per 1.73 m2 and Group C,
OSBP 140 mmHg and eGFR 15 mL/min per 1.73 m2. For all three
groups subjects were required to be on at least 3 anti-hypertensive
medications (including 1 diuretic), or to have documented drug
intolerance such that they are unable to take 3 anti-hypertensive
drugs. Responder analysis was also performed using a 5mmHg
reduction in ambulatory systolic measurement to deﬁne responders.
RESULTS 133 patients from Group A (average age 61.6  9.5 yrs taking
on average 4.3 2.3 anti-hypertensive medications) were included.
Bilateral renal nerve ablation was performed using a percutaneous
femoral approach. Baseline average OSBP was 181.9  16 mmHg,
average ofﬁce diastolic BP (ODBP) was 97.8  15.9 mmHg, average
24hr ambulatory SBP (ASBP) was 159.4  17 mmHg, and average 24hr
ambulatory DBP (ADBP) was 88.7  12.9 mmHg. At present, 119 6-
month and 88 12-month follow-up visits are completed. The average
reduction in OSBP/ODBP was 18.5/8.4 mmHg and 18.2/9.5 mmHg at 6-
and 12-month follow up respectively (p<0.0001 for all). The average
reduction in ASBP/ADBP was 7.1 /3.8 mmHg (p<0.0001 for both) and
9.8 /4.2 mmHg (p<0.001 for both) at 6 and 12M follow up respectively.
Neither eGFR nor serum creatinine changed signiﬁcantly from base-
line at either 6 or 12-months follow up. The following baseline factors
were associated with the responder group at the 90% conﬁdence
level: younger age, less sleep apnea, higher eGFR, lower serum
creatinine, higher systolic & diastolic ambulatory pressures.
CONCLUSIONS In this real world, post-marketing study we demon-
strate that multi-electrode renal denervation results in durable, highly
signiﬁcant and safe lowering of both ofﬁce BP and ambulatory BP
parameters in patients with severe uncontrolled hypertension up to 12
months following treatment.
